ABSTRACT
Objective The purpose of our study is to investigate the clinical value of virtual touch tissue quantification (VTQ)in the differential diagnosis of the benign and malignant liver tumor.Methods VTQ was used to inspect 53 patients with liver space-occupying lesions.Results After choosing the little lesions (the largest diameter less than 35 mm) from all the case groups,the VTQ value of the malignant group was higher than the hepatic hemangioma group (with significant differences among the different groups,P ＞0.05).Through the analysis of receiver operating characteristic curve (ROC),the optimal cutoff point as diagnosis reference value for differential diagnosis between malignant and benign groups was available.When the Area under the curve was 0.778,and with the VTQ value of 1.91 m/s,the sensitivity,specificity and Youden index was 78.6％,90.0％,0.686 respectively.The correlation analysis showed that the VTQ values of the lesion was positively correlated with the largest diameter of the lesion in the liver hemangioma group,with significant statistically differences (P ＜ 0.05).The correlation index was 0.812.Conclusions VTQ could provide a new effective way to benign and malignant liver lesions in differential diagnosis.
ABSTRACT
0.05). But in repeated chemotherapy, the period of leukopenia recovered to normal was shorter in group B than that in group A or group C. The effects of the domestic rhG-CSF on leu-copenia induced by chemotherapy were similar to the imported products of same dose. CONCLUSION: Low dose of domestic rhG-CSF (75?g) can effectively treat the leukopenia caused by postchemotherapy in patients with gynecological tumors. 150?g of domestic rhG-CSF is more effective than 75?g of domestic or import rhG-CSF in treating leukopenia in repeated chemotherapy.
ABSTRACT
Purpose:To evaluate the therapeutic effect of paclitaxel and platinum containing chemotherapy (cisplatin or carboplatin) in women with epithelial ovarian cancer.Methods:We assigned 16 cases with advanced epithelial ovarian cancer after initial surgery to receive paclitaxel and cisplatin or carboplatin. Pcalitaxel (135 mg/m 2,over a period of 10 hours ) was administered iv once every 3 to 4 weeks, 24 control cases were treated with "CAP" or "CVP" regimen. Results:The overall median survival was significantly longer in the paclitaxel platinum group than in the cisplatin cyclophosphamide group (median, 35 vs. 22.5 months, P